Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. fasnagel

FasNaGel

NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO THE NERVES FASCIA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 FasNaGel project word cloud

Explore the words cloud of the FasNaGel project. It provides you a very rough idea of what is the project "FasNaGel" about.

negative    absences    worldwide    gdp    anti    report    billion    perform    enormous    nanostructured    prematurely    hyaluronic    plane    disability    validation    sickness    labour    staff    team    indirect    100    biocompatible    coming    carrier    fasnagel    medicines    effectiveness    suffers    exit    size    deducting    marketing    functional    quality    inflammatory    wrongly    2014    80    hydrogel    chronification    30    biodegradable    20    losses    reduce    track    professional    fast    depression    post    drug    steroidal    market    euros    pain    med    consists    total    start    medical    made    porous    estimates    imed    271    greatest    commercialization    provides    nanomedicinal    recovery    thorough    feasibility    102    life    personal    people    direct    properly    acid    multiply    policies    first    surgery    acute    works    time    prevent    treatment    operative    population    healthcare    huge    mill    few    60    149    patients    days    chronic    unemployment    productivity    started    injectable    containing    disorders    sme    world   

Project "FasNaGel" data sheet

The following table provides information about the project.

Coordinator		 I+MED S.COOP. PEQUENA 

Organization address
address: CALLE ALBERT EINSTEIN 15
city: VITORIA-GASTEIZ
postcode: 1510
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website https://imasmed.com/portfolio-items/programas-investigacion/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    I+MED S.COOP. PEQUENA ES (VITORIA-GASTEIZ) coordinator 50˙000.00

Map

 Project objective

Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more sickness absences at work, productivity losses, unemployment, etc.). Chronic pain is one of the major reasons (30%) why people exit the labour market prematurely. 20% of current population in Europe suffers from chronic pain (102 mill.) and up to 50 % of that pain comes from wrongly treated acute post-operative pain. The total direct and indirect healthcare costs for chronic pain disorders in Member States have an EU average of 2.4 % of GDP and a cost of 271 billion euros per year. When acute pain is not properly treated in the first few days, it can become chronic. About 40-60% of patients report pain chronification after surgery. Current medicines do not prevent chronic pain from the start and have side effects. “Fast track” approaches have started to take the lead in pain management policies. Based on these approaches I Med´s team works since 2014 in the development of FasNaGel, a new nanomedicinal product, unique in the world. It consists of a biocompatible and biodegradable injectable carrier, made of porous nanostructured hyaluronic acid hydrogel containing a non-steroidal anti-inflammatory drug that i) efficiently, provides a 100% of functional recovery after surgery in one third of the time, ii) is easy-to-use by medical staff, and the most important iii) increases by 80% the treatment effectiveness. FasNaGel will reduce the overall treatment costs in Europe, deducting indirect costs coming from acute pain up to €149 billion. The objective of this proposal is to be able to perform a thorough feasibility study for the validation of the production and commercialization of this novel product. FasNaGel marketing will have a huge of a SME such as iMed, who estimates to multiply the team size by 8 in 7 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FASNAGEL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FASNAGEL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More